Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours

Background: Peptide receptor radionuclide therapy (PRRT) is an approved treatment modality for gastroenteropancreatic neuroendocrine tumours (GEP NETs), Although Phase III randomised clinical trial data is not available for NETs of other site of origin, in practice, PRRT is used more widely in clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Lisi Elizabeth, Chan, David L., Thomas, David, Du, Yang, Tincknell, Gary, Kuchel, Anna, Davis, Alexander, Bailey, Dale L., Pavlakis, Nick, Cehic, Gabrielle, Macdonald, William, Wyld, David, Segelov, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343632/
https://www.ncbi.nlm.nih.gov/pubmed/32676165
http://dx.doi.org/10.18632/oncotarget.27659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343632/
https://www.ncbi.nlm.nih.gov/pubmed/32676165
http://dx.doi.org/10.18632/oncotarget.27659

Ejemplares similares